

Nuclear Instruments and Methods for the Campaign against Cancer

Gérard Montarou

*Laboratoire de Physique Corpusculaire Clermont
IN2P3/CNRS*

- **Introduction: a short historical review**
- **Applications in medical diagnostics**
- **Applications in conventional cancer radiation therapy**
- **Hadrontherapy, the new frontier of cancer radiation therapy: Proton and Carbon therapy**
- **Other tools (Peroperative probes)**
- **Organisation of Physics-Biology interface activities at IN2P3 in France**

1. Introduction


Fundamental research in nuclear and particle physics and medical applications

Progress in Health and life sciences had always been strongly correlated to technological developments in physical science, especially in Nuclear and High Energy Physics.

- **November 1895 : discovery of X rays**




Wilhelm Conrad Röntgen



- **December 1895 : first radiography**




The beginning of modern physics and medical physics



Henri Becquerel
(1852-1908)


1896:

Discovery of natural
radioactivity



Thesis of Mme. Curie – 1904


α , β , γ in magnetic field



About one hundred years ago

1898

Discovery of radium



Marie

Skłodowska Curie Pierre Curie
(1867 – 1934) (1859 – 1906)

First applications in cancer therapy

STOCKHOLM



1902

1912

Basic concept
Local control
of the tumour



1908 : first attempts of skin cancer
radiation therapy in France
(“*Curiethérapie*”)


A big step forward...

...in physics and in


- **Medical diagnostics**
- **Cancer radiation therapy**

due to the development of three fundamental tools

- **Particle accelerators**
- **Particle detectors**
- **Computers**




M. S. Livingston and E. Lawrence
with the 25 inches cyclotron




Geiger-Müller counter built by
E. Fermi and his group in Rome

1930: invention of the cyclotron

Spiral trajectory of an accelerated nucleus




Modern cyclotron



**Ernest Lawrence
(1901 – 1958)**

- They are the “eyes” of particle physicists
- A very impressive development in the last 100 years
 - From the Geiger counter to ATLAS and CMS !
- Crucial in many medical applications

One example: the multiwire proportional chamber



**Georges Charpak, CERN
physicist since 1959,
Nobel prize 1992**

- Invented in 1968, launched the era of fully electronic particle detection
- Used for biological research and could eventually replace photographic recording in applied radio-biology
- The increased recording speeds translate into faster scanning and lower body doses in medical diagnostic tools based on radiation or particle beams


2. Applications in medical diagnostics

→ Medical Imaging systems are more and more powerfull and complex

→ Combining different modality of which nuclear imaging is a major component


→ Early Diagnostics is essential !

Computer Tomography (CT)



Abdomen

Detectors rotated
Around the patient
with the X ray tube



X ray tube

CT Scan

- Measurement of the electron density
- Information on the morphology

Nuclear Magnetic Resonance Imaging

1938-1945

Felix Bloch and Edward Purcell

discover and study

NMR

MRI was first a spectroscopy technique for chemistry, physics and biology

In the 70ths, interest grew-up for medical application of MRI, and first human imagery was done

In the 80th, technical progress in temporal resolution and in spatial as well so that RMI imagery became one of the most important clinical imagery technique



In 1954 Felix Bloch became the first CERN Director General

MRI : magnetic stuff !!

External magnetic field
 $B_0 = 3 \text{ T}$

Electromagnetic field B_1
(Radio-frequency or RF)

Magnetic properties of the NUCLEI

The nuclear *SPIN* → no radioactivity !!

- characterized by a spin number I
- *quantum mechanics !!*
- a nucleus with $I \neq 0$ behaves like a small magnet


The Hydrogen nucleus

→ the most abundant ($\sim 2/3$ of the atoms in living tissues)

Behaviour of the nuclei interacting with :


1° An external magnetic field $B_0 \rightarrow$ Equilibrium state

When no magnetic field B_0 is applied
 \rightarrow spin orientation is completely random



When a static magnetic field B_0 is applied
(along axis z)

\rightarrow spins are aligned with the field B_0 .



Somme of them have parallel orientation (**spin-up**), other have antiparallel orientation (**spin-down**)

The two different orientations correspond to two different energies: E_1 corresponds to spin-up; E_2 corresponds to « spin down ».

\rightarrow difference $\Delta E = E_2 - E_1$ is proportional to the strength of the field B_0 .

Number of spins with energy E_1 is larger than number of spins with energy E_2 are so that a **macroscopic resultant magnetic field M_z appears parallel to B_0 .**

Interaction with B_0

→ Rotation or **precession** about the axis of the magnetic field B_0 with frequency :



$$\omega_0 = \gamma B_0$$

ω_0 = Larmor frequency

γ = gyromagnetic ratio


At the equilibrium state :

- The rotation is **not in phase**
- no transverse magnetization M_{xy}



Summary of the equilibrium state :

1. spin orientation « up » > « down »
→ longitudinal magnetization M_z
2. precession
→ no transverse magnetization M_{xy}




Behaviour of the nuclei interacting with :

2°) An electromagnetic field B_1 (RF) \rightarrow Disturbance

Resonance phenomenon


TRANSITIONS



Transitions $E_1 \rightarrow E_2$

$\Rightarrow M_z$ decreases

REPHASING



Phase coherence increases


$\Rightarrow M_{xy}$ increases

RF frequency = Larmor frequency = ω_0

Behaviour of the nuclei interacting with :


Relaxation \rightarrow Back to the equilibrium state

TRANSITIONS



**Transitions $E_2 \rightarrow E_1$
 $\Rightarrow M_z$ increases
 $\Rightarrow T_1$ relaxation**

DEPHASING



**Dephasing
 $\Rightarrow M_{xy}$ decreases
 $\Rightarrow T_2$ relaxation**

Signal localization

Up to now → the signal received contains information from the entire body !!

Use field gradients along the 3 axis to spatially encode the signal in three steps :


1. Application of a gradient G_z → Slice selection

Resonance Phenomenon → $\omega_{RF} = \omega_0$!!!

Before G_z is applied : all the spins precess with same frequency ω_0
→ all could resonate !!

During application of G_z : the spins precess with $\neq \omega$

→ only spins with frequency = ω_{RF} resonate



2. Application of a gradient G_x → Frequency-encoding → columns selection

Before G_x is applied : all the spins precess with same Larmor frequency ω_0

During application of G_x : the spins precess with \neq frequencies

⇒ Fourier Transform of the signal allows discrimination between columns !


3. Application of a gradient G_y → Phase-encoding → lines selection

After application of G_y : all the spins precess again at same Larmor frequency,
but with different phase shifts from line to line...

Contrast in MRI

Grey-level images :

→ the intensity of a voxel depends on the intensity of the corresponding signal





Contrast depends on :

1. tissue properties : T_1 , T_2 , ρ → user-independent

2. sequence parameters : T_R , T_E , ... → user-dependent

T_R = repetition time = time interval between two RF pulses

T_E = echo time = when the acquisition is performed




	T_1 (ms)	T_2 (ms)	proton density ρ
WM	500	75	0.65
GM	750	90	0.8
CSF	3000	200	1.0

Contrast in MRI

T2-weighted image : long T_R – long T_E

T1-weighted image : short T_R – short T_E



$T_R = 3370 \text{ ms}$


$T_E = 112 \text{ ms}$



CSF

GM

WM



$T_R \sim 500 \text{ ms}$

$T_E \sim 10 \text{ ms}$




WM

GM

CSF

A MRI scanner



MRI is based on nuclear properties of the nuclei (the spin)

→ morphologic & functional imaging system

→ But it does not use at all radioactivity

Instead of nuclear imaging systems that give access to the metabolism of the organs by the way of radioactive molecules (mainly glucose based molecules)

→ radioactive molecules are injected into the patient

→ trapped in the cells that try to metabolize it

→ Concentration builds up in proportion to the rate of glucose metabolism

→ Radioactive molecules decay with gamma emission

→ Tumors have a high rate of glucose metabolism and appear as “hot spots” in images

Gammas are detected by systems using scintillating crystals coupled to photodetectors and front-end electronics

The two main nuclear imaging techniques are :

→ Single Photon Emission Computer Tomography **SPECT**

(using γ)

→ Positron Emission Tomography **PET** (using β^+)

Combined PET + MRI + CT ?

« **Multimodality imaging** »

MRI → morphologic & functional images


PET → functional & metabolic images




Fusion of different kind of images

→ **improve clinical diagnostic**

SPECT = Single Photon Emission Computer Tomography



In reactors slow neutrons produce




emission of gamma
of 140 keV

Emilio Segrè

1937: Discovery of element 43 "Technetium" ${}^{97}\text{Tc}$ (2.6 My)

1938: discovery of ${}^{99\text{m}}\text{Tc}$
with E. McMillan




SPECT scanner

85% of all nuclear medicine examinations use technetium


... liver, lung, bones ...

- Measurement of the density the molecules which contain technetium

- Information on morphology and/or metabolism



Lead collimators to channel the gammas of 0.14 MeV




Positron Emission Tomography (PET) How does it work?


β^+ emitting Isotopes

→ T1/2 :


^{18}F	^{15}O	^{11}C	^{13}N
114 min.	2 min.	20 min	10 min



Thermalization of the positron in biological tissue



Positron Annihilation : $e^+ e^- \rightarrow \gamma \gamma$




Positron Emission Tomography (PET) How does it work?

These isotopes are produced by proton reaction on stable nuclei using a cyclotron (IBA, Cyclopharma..) → **ideal configuration cyclotron should be close of the PET in hospital**



General electric
PET tomograph



CYCLONE 10/S Standard Installation

Cyclotron
Protons



~15 MeV, ~50 μ A



IBA

90 % of the radiopharmaceutical molecules used in PET is FluoroDesoxyGlucose with $^{18}\text{F} \Rightarrow \text{FDG}$

- H_2^{18}O water is bombarded with protons to produce ^{18}F
- Fluoro-Deoxy-D-Glucose (FDG) is synthesized



- FDG is transported to the hospital
- FDG is injected into the patient
- FDG is trapped in the cells that try to metabolize it
- Concentration builds up in proportion to the rate of glucose metabolism

To few FDG production centers !! → bottleneck for PET use in hospital

Active research field at the interface between nuclear physics and chemistry for the production of other kind of radiopharmaceutic


→ Accélérateur pour la Recherche en Radiochimie et Oncologie à Nantes Atlantique (ARRONAX)

Research center for production of innovative radioisotopes


→ IBA Cyclotron 70 MeV, 750 microamps



One signal event = detection of two 511 keV γ in time coincidence in two back to back detectors




Positron Emission Tomography (PET)= electronic collimation




Signal and Noise Events


Random events
= Noise



True event
= Signal



Noise = Random Coincidence in time




Delayed coincidence method





$$C_t = C_m - C_d$$


Random Coincidence estimation = delay time window counts



2D (septa) vs. 3D (no septa)




Septa are interring collimators that shield detectors from out-of-plane annihilation γ -rays And scatter rays at a conventional 2D out-of-plane mode scan.



In the 3D-mode scan, septa are retracted for inter-plane coincidence at over all planes. Therefore the system efficiency can be greatly increased. But the retraction of septa increases detection events of out-of-plane annihilation γ -rays and scattered γ -rays.

Energy window selection to cuts scatter events





Scatter decreases with high energy threshold but depends on energy resolution

Noise Equivalent Counts (NEC)

True count rate does not directly indicate the signal-to-noise ratio in a PET image.




The NEC defines an effective true count rate by accounting for the additional noise from scatter and random events.



70-cm long x 20-cm diameter

NEMA 2001 (body)

HOW A PET IS MADE OF ?



**PMT is magnetic field sensitive
Cannot be use for PET+MRI*


HR+ SIEMENS

32 rings of 576 crystals.

2D/3D.

transversal spatial resolution : 4,5mm


axial resolution : 3,6mm



Pharmacology studies use animal models → Smaller PET for Animals

Dedicated small animals multimodal imaging Platforms

→ Imaging system developed in laboratory by physical groups but used by biological groups




A very small PET for mouse
The RatCAP PET in Brookhaven

Examples of multimodal platforms


→ AMISSA platform (μ CT/ μ SPECT/ μ PET) at IPHC Strasbourg

→ ImXgam platform (μ CT/ μ PET) at CPPM Marseille

The AMISSA MULTIMODAL PLATFORM (IPHC)





Rotating CT part



SPECT part


The rat should go inside there !

Some Images !




The imXgam MULTIMODAL PLATFORM (CPPM Marseille)

Based on the ClearPET from EPFL Lausanne but modified to achieve simultaneous small animal X-ray CT-scanner based on ultra fast hybrid pixels in collaboration with the Developmental Biology Institute of Marseille-Luminy (IBDML).



The original ClearPET




X ray source

Hybrid Pixel detectors (XPAD3)

118×76 mm² with 130×130 μm² pixels

How to improve PET imaging


1°) As we already seen in previous slides, extensive use of multimodality imaging → PET+CT is now currently used in hospital



How to improve PET imaging


→ PET+MRI is quite difficult

MRI scanners rely on very strong, very smooth magnetic fields that can easily be disturbed by metallic objects inside the scanner. At the same time, those magnetic fields can seriously affect the detectors and electronics needed for PET scanning




2° Scatter corrections

3° Attenuation corrections



PET+MRI at Cavendish University


Scatter Correction



Before
Scatter
correction

After
Scatter
correction

Single Scatter - Model based correction
Calculate the contribution for an arbitrary scatter point using the Klein-Nishina equation



Attenuation Correction



*Attenuation correction with
radioisotope transmission scan*

20 mCi ^{137}Cs source - 662 keV

$$A = 1 / e^{-\mu d}$$

d = length of chord through tissue


μ = attenuation coefficient




How to improve PET imaging → Time of Flight PET

Basic Concept of Time-of-Flight-PET


Localization of source along line of response depends on timing resolution Δt



TOF PET vs. Conventional PET



**Conventional PET
Image Formation**



**TOF PET
Image Formation**

More precise localization of annihilation event reduces noise

$\Delta \text{sens.} = \frac{D}{\Delta x}$

D Lesion detectability model using numerical observer and iterative reconstruction


Δx

$\Delta x = c * \Delta t / 2$

D: Object size →

c : Speed of Light

Δt : system timing res.




Data courtesy of J. Karp, University of Pennsylvania

Image comparison (phantoms) ToF – non ToF

Imaging Time

Non-Time of Flight

Time of Flight





Time of flight reduces noise resulting in higher image quality, shorter scans or lower dose.

*Phantom studies (IEC spheres in a 27 cm diameter and 35 cm diameter cylinder)
Data of J. Karp, University of Pennsylvania*



no TOF

300 ps TOF



1 Mcts



5 Mcts




10 Mcts




*Time-of-Flight :
list-mode iterative reconstruction*

- 5Mcts TOF ○ 5Mcts
- 1Mcts TOF ● 1Mcts



PHILLIPS GEMINI TF™ : Performance summary



PET scanner

LYSO : 4 x 4 x 22 mm³

28,338 crystals, 420 PMT's
crystal gap: 0.75 μm

2 τ = 4 ns

70-cm bore, 18-cm axial FOV

CT scanner

Brilliance™ 16 or 64 slice

Spatial resolution @ 1cm off center:

transaxial (mm)

axial (mm)

Sensitivity (kcps/MBq):

Energy resolution (FWHM):

Scatter fraction @ 440 keV:

Peak NEC (kcps@mCi/ml):

NEMA

LOR-TOF

4.8

4.3*

5.2

4.2*

6.6


12%

29%

97@ 0.42

eff. NEC > x 4

TruFlight™: Clinical Image Quality Improvement



list-mode
non-ToF

list-mode
ToF

Data courtesy of J. Karp, University of Pennsylvania

PHILLIPS GEMINI TF™ in “Val de Grace” hospital (Paris)
Typical TOF Performance between 450 and 500 ps

→ To improve TOF resolution, we should **go below 200 ps**

TOF resolution:

More brilliant and faster crystals (LSO, LaBr3:Ce,????)

Fast photodetector (from PMT to SiPM and MCP-PMT)

Fast electronic (sampling method → > 1 GHz/s)

Or use different technology like RPC

Current Crystal : LSO (orthosilicate of Lutetium doped with cerium)

25 000 photon/MeV 40 ns scintillation time

→ Easy to manipulate (not hygroscopic) and relatively cheap

→ Could be improved with Calcium doping



Ca concentration (%)	Light output (photons/MeV)	Decay time (ns)
0.0	30900	43.0
0.1	38800	36.7
0.2	36200	33.3
0.3	32400	31.3
0.4	34800	31.0


Light output and decay time values are the average of multiple samples.

Most efficient Crystal : LaBr₃ (Lanthanum Bromide doped with cerium)



40 000 photon/MeV 15 ns scintillation time

hygroscopic and expensive


Could be improved with Cerium doping



LaBr₃ (Cerium X%)




Fast Timing Devices



Multi-anodes PMTs

Dynodes

QE	30%
CE	90%
Rise-time	0.5-1ns
TTS (1PE)	150ps
Pixel size	2x2mm²
Dark counts	1-10Hz
Dead time	5ns
Magnetic field	no
Lifetime	-



Si-PMTs

Quenched Geiger

QE	90%
CE	70%
Rise-time	250ps
TTS (1PE)	100ps
Pixel size	50x50mm²
Dark counts	1-10MHz/pixel
Dead time	100-500ns
Magnetic field	yes
Lifetime	?




MicroChannelPlatePMTs

Micro-Pores

QE	30%
Rise-time	60-200ps
TTS (1PE)	20-30ps
Pixel size	1.5x1.5mm ²
Dark counts	1-10 kHz/cm ²
Dead time	1ms
Magnetic field	15kG
Lifetime	~ Coulomb total charge

- **Constant-fraction-discriminator (CFD).**
- **CFD + additional pulse height correction.**
 - A slight time-walk as number of photoelectrons corrected by the QTNT + ADC
- **Waveform sampling (a'la Gary Varner's design from U. of Hawaii).**
 - The most powerful timing method.
- **Double-threshold timing on both leading and trailing edges.**
- **Single threshold on both leading and trailing edges.**
 - The most simple.



Alternative technology



Use of stack of Resistive Plate Chambers (RPC)

1°) photoconversion of photon to electron

2°) detection of the secondaries produced electron

→ Gaseous detector

→ Absorption of a RPC is limited → need a stack of detectors



A. Blanco et al NIM 2003 & 2006


Comparison between different small animal PET parameters and the expected parameters of the RPC-PET

	Quad HIDAC (32 modules) [8]	YAP-PET [2]	MicroPET [®] II [3]	RPC-PET ^a
Central point absolute sensitivity (cps/kBq)	18 ^b	17.3 ($\varnothing = 150$ mm) ^c	22.6 ^d	9 ^e
Image spatial resolution (mm) FWHM	1 mm (uniform)	< 1.8 (uniform)	1.07	≤ 0.6 (uniform)
Time resolution (ns) FWHM	—	2	3	< 300 ps
Window time (ns)	< 80	< 5	< 10	< 1
FOV (mm)	170 \varnothing × 280 (axial)	40 × 40 × 40	160 \varnothing × 49 (axial)	150 \varnothing × 300 (axial)

WP9 of GDR MI2B: IPHC, LPC Clermont, CPPM, IMNC Orsay
Use of Innovative Developments for High Energy Physics to
go below 200 ps TOF resolution:


3. Applications in conventional cancer radiation therapy

Radiotherapy with X-rays




- Electron linacs to produce gamma rays (called X-rays by medical doctors)
- 20'000 patients/year every 10 million inhabitants

Production of X "quanta"



Computerized Treatment Planning System (TPS)



• CT scan data are used to


• design the volume to be irradiated

• choose the radiation fields

• calculate the doses to the target and to healthy tissues

• The dose is given in about 30-40 fractions of about 2 Gray


The problem of X ray therapy



The problem of X ray therapy

Solution:

- **Use of many crossed beams**
- **Intensity Modulation Radiation Therapy (IMRT)**




9 different photon beams

The limit is due to the dose given to the healthy tissues!

Especially near organs at risk (OAR)

Multi leaf collimators and IMRT



Multi leaf collimator which moves during irradiation

- It is possible to obtain concave dose volumes
- Time consuming (used for selected cases)

The “gamma knife”

- Proposed in 1967 by Lars Leksell (neurosurgeon) and Borje Larsson (physicist) at Karolinska Institutet, Stockholm
- Treatment of selected brain tumors, arteriovenous malformations and brain dysfunctions
- Small volume diseases (located in the head) treated in one session only (“stereo-tactic radio-surgery”)
- Today, more than 30000 patients every year



Lars Leksell poses with his Gamma Knife head frame



The original 1967 Leksell Gamma Knife



Today's Leksell Gamma Knife



201 ⁶⁰Co radiation sources


The “cyber-knife”

- **Lightweight 6 MV linear accelerator to produce X-rays mounted on a robotic arm**
- **Use of X-rays taken during treatment to establish the position of the lesion and monitor the treatment**
- **Possibility of multiple fractions**
- **Used to treat small volume tumours (ex . Brain, head & neck, lung, spine, abdomen and pelvis) and lesions throughout the spine**



Intense Monochromatic X-ray source

LAL at Orsay in collaboration with CELIA de Bordeaux, Thalès, Institut Gustave Roussy and SOLEIL, initiate the project ThomX to design a very intense monochromatic X ray source → WP1 of GDR MI2B




In such an approach, contrast agents (marker) are injected into the patient, targeting tumoral cells. Tumours are irradiated by a quasi-monochromatic X-radiation near the energy of the X absorption peak, in order that the marker's molecules goes to resonant states and have strong local interaction with tumour cells

It is also possible by subtracting images performed at energies below and above the Kalpha threshold of the marker (Iodine, Gadolinium, cis-Platinum), to increase spectacularly the visibility of tissues charged with marker's molecules


The use of this property in oncology would make it possible to distinguish tumours of low size, or difficult to distinguish in the middle of an important photonic noise due to the diffusion in biological tissues; the angiographic imagery would be also strongly improved.

The problem of organ motion




Possible solutions:

- Respiratory gating
- Image Guided Radiation Therapy (IGRT)




Can we do better ?

2 X ray beams



9 X ray beams (IMRT)




A question for a particle physicist

Are there better radiations to attack the tumour and spare at best the healthy tissues?


Answer : BEAMS OF CHARGED HADRONS

4.Hadrontherapy

The frontier of cancer radiation therapy




The Bragg peak



Depth dose distribution of various radiation modalities


Depth-dose curve for a single beam of 254 and 300 MeV/u carbon, and 135 MeV proton

Both particles, protons and Carbon ions interaction with matter produces a limited energy release in the first part of their path, where the beam has more energy. When the beam energy decreases, and in the final part of the trajectory there is a sudden and strong energy release with a precise and sharp decrease to zero energy release in a few millimetres. This feature produces the well-known **Bragg Peak** in the curve of the relative dose vs. trajectory length.




If projectile energy is spread
→ "Spread out Bragg Peak" (SOBP)

The basic principles of hadrontherapy




- **Bragg peak**
 - Better conformity of the dose to the target → healthy tissue sparing
- **Hadrons are charged**
 - Beam scanning for dose distribution
- **Heavy ions**
 - Higher biological effectiveness (RBE)

Why ions have a large biological effectiveness?



Ions have high LET (Linear Energy Transfer)

Let's go back to physics...





Carbon $Z \geq 6$

$Z < 6$ Proton

Projectile fragments

Target fragments


Target fragments



Why carbon is better than proton ?


Balistic

→ Less lateral scattering for carbon (X, Y)




→ Lower Tail of dose after Bragg Peak for proton

Comparison of dose profiles of protons and carbon





Dose distribution: active scanning

Longitudinal plane



Transverse plane




A spot corresponds to a fixed position in x and y
In a slice, where dose is set

A slice in depth corresponds to a fixed energy and a value along the beam axis

New technique developed mainly at GSI and PSI


Single beam comparison




Protons and ions are more precise than X-rays

Tumour between the eyes


9 X ray beams



1 proton beam




Verifying the position of the irradiation field




W.Enghardt et al. ,
FZR Dresden

TPS → dose plan



Dose
Measured

European Summer University Strasbourg, July 2009



Dose
Simulated

G.Montarou

What are the key points in Hadrontherapy ?

To define the treatment (TPS), one should be able to

- (1) Know the dose and how it is deposited in the biological tissue**
- (2) Know what is the biological effect of the dose in the tissue**

First item needs to know exactly about all the physical processes that are involved in the reaction of the beam with the medium

- That means to be able to predict and simulate these reactions
- We should know the differential cross sections of the physical processes
- These are still not completely measured at such energies
- Experimental data has been measured at low energy at GANIL (LPC Caen, IPHC, IPNL) WP4 of GDR MI2B
- Experimental program at higher energy is planned at GSI using already existing experimental set-up (Aladin spectrometer) G Cutonne, LPC Caen, IPHC, CEA, IPNL, GSI

What are the key points in Hadrontherapy ?

First item needs also to CONTROL how and where the dose is deposited in the tissues

- That means to be able to detect physical signals (outgoing particles) with a close correlation to the macroscopic dose in a small volume**
- Need of a quality control procedure that could be performed in time during the treatment and in beam conditions**

Second item needs to know Biological effectiveness of hadron on different kinds of cells



- That is means to measure the survival curves of these cells as a function of the dose (Gy) → radiobiological experiments at the interface of physics and biology**
- To define Biological models that could be used by doctors to define a specific treatment for each treated patient (LEM model in GSI, M Beuve et al ..)**

How to Control in situ the Dose ?

Two methods

1. In beam PET
2. Single nuclear photon detection (prompt gammas)

Special PET close to the patient should be able to detect 511 KeV from decay of radioisotopes produced during beam interaction (mainly ^{11}C)



How to Control in situ the Dose ?

1998 - GSI pilot project (G. Kraft)

**200 patients treated
with carbon ions**



PET on-beam

How to Control in situ the Dose ?

Problems of such a method :


- 1°) radioisotopes of short half life time ^{11}C (20 min), ^{15}O (2min), ^{10}C (10s)
 - 2°) Low activity (~10 KiloBq) in comparison with clinical TEP (250 MegaBq)
 - 3°) need at least tenth of minutes to have sufficient statistics
 - 4°) metabolic washout of the radioisotopes in the body (blood)
- To be efficient in beam PET need TOF resolution less than 200 ps

Other method is to detect nuclear high energy gammas coming from nuclear reaction of the beam → correlation with the range of the projectile

GANIL :

^{13}C @ 73 MeV/u → PMMA

[Testa et al., Appl. Phys. Lett. 2008]



But also many neutrons

→ Gamma should be selected by the experimental set-up


→ Use of TOF

How to Control in situ the Dose ?


National project GAMHADRON (LPC Clermont; IPNL, CEA/LIST, INSA Lyon) and European Project ENVISION (WP9 of GDR MI2B)

→ Test and define an experimental setup to detect high energy nuclear gamma

- SPECT technology (passive collimator)
- Compton Camera



SPECT technology (passive collimator)



Compton Camera

Number of potential patients

X-ray therapy

every 10 million inhabitants: 20'000 pts/year

Protontherapy

12% of X-ray patients = 2'400 pts/year

Therapy with Carbon ions for radio-resistant tumours


3% of X-ray patients = 600 pts/year

Every 50 M inhabitants

- Proton-therapy
5 centres
- Carbon ion therapy
1 centre

TOTAL about 3'000 pts/year

every 10 M



Present and “near” future of hadrontherapy


● Proton-therapy is “booming”! *(for more information see PTCOG, www.ptcog.com)*

- **Laboratory based centres: Orsay, Nice, PSI, INFN-Catania, ...**
- **Hospital based centres: 3 in USA, 4 in Japan and many under construction (USA, Japan, Germany, China, Korea, Italy, ...)**
- **Companies offer “turn-key” centres (cost: 50-60 M Euro)**

● Carbon ion therapy



- **2 hospital based centres in Japan**
- **Pilot project at GSI**
- **3 hospital based centres in Germany (Heidelberg, Marburg, Kiel)**
- **1 hospital under construction in Italy (CNAO in Pavia)**
- **2 projects approved (France and Austria)**
- **European network ENLIGHT**

The map of hadrontherapy




The accelerators used today in protontherapy


CYCLOTRONS (Normal or SC)



SYNCHROTRONS



OR



MGH - IBA

CYCLOTRONS

- Almost continuous beam
- Fixed energy

Shizuoka - MITSUBISHI

SYNCHROTRONS

- Beam ON and OFF
- Continuous energy

Japan: 4 proton and 2 carbon ion therapy centres

WAKASA BAY PROJECT
 by Wakasa-Bay Energy Research Center
 Fukui (2002)
 protons (≤ 200 MeV) synchrotron
 (Hitachi)
 1 h beam + 1 v beam + 1 gantry

TSUKUBA CENTRE
 Ibaraki (2001)
 protons (≤ 270 MeV)
 synchrotron (Hitachi)
 2 gantries
 2 beam for research


HYOGO MED CENTRE
 Hyogo (2001)
 protons (≤ 230 MeV) - He and C ions (≤ 320 MeV/u)
 Mitsubishi synchrotron
 2 p gantries + 2 fixed p beam + 2 ion rooms

KASHIWA CENTER
 Chiba (1998)
 protons (≤ 235 MeV)
 cyclotron (IBA – SHI)
 2 Gantries + 1 hor. beam

HEAVY ION MEDICAL ACCELERATOR
 HIMAC of NIRS (1995)
 He and C (≤ 430 MeV/u) 2 synchrotrons
 2 h beams + 2 v beams


SHIZUOKA FACILITY
 Shizuoka (2002)
 Proton synchrotron
 2 gantries + 1 h beam

**2000 patients
 with carbon ions**



**50 patients
 with carbon ions**



The eye melanoma treatment at INFN-LNS in Catania





- **LNS Superconducting cyclotron**
- **65 MeV protons**
- **92 patients (oct 2005)**

The Loma Linda University Medical Center (USA)

- First hospital-based proton-therapy centre, built in 1993
- ~160/sessions a day
- ~1000 patients/year



HIT – University of Heidelberg



- Hospital based centre
- Project started in 2001
- First patient treatment foreseen in 2007


5. Some other examples of application

***→ Peroperative Probes
Detection system to help tumor detection during
surgery***

Per Operative Probes


System to help tumour detection during surgery

Sentinel Lymph Node procedure



Use of camera POCI (IMNC Orsay)
Previous and during surgery

Lymphoscintigraphy made with
a usual gamma camera (SPECT)
And POCI camera



IPHC Per Operative Probe and gamma camera

γ probe




Sentinel Lymph Node procedure

To reinforce before the surgery the diagnostic obtained the day before by lymphoscintigraphy (γ camera).

To localize the radioactive lymph node during the surgery (probe & γ camera).

To confirm after the surgery the removal of the all radioactive lymph nodes (γ camera).

γ camera



6. Organisation of medical application activities at the interface between physic and biology at IN2P3

→ IN2P3 is the institut of French CNRS in charge of Nuclear and High Energy Physics

→ 17 laboratories → (Institut PluriDisciplinaire Hubert Curien in Strasbourg)

→ There is a group working at the interface between Life Sciences and Physics in almost each laboratory

→ MI2B joined Research Group (GDR in French) to help coordination of all these activities as high energy physics project





R&D on TOF PET
Physics Simulation for
biology and oncology



R&D on Dosimetry
Physics Simulation for
Hadrontherapy
Physical data
measurements



R&D on monochromatic X ray
source



R&D on hadrontherapy
control quality
Physics Simulation for
biology and oncology



R&D on imaging for neurology
and oncology
Peroperative Probes
Physics Simulation for
biology and oncology



Radiobiology (microbeam)
Physics Simulation for
biology and oncology



Small Animal multimodal imaging
platform (Amissa)
Peroperative probes
R&D on TOF PET
Physical data measurements

Small Animal multimodal
imaging platform (ClearPET)
R&D on TOF PET
Physics Simulation for
biology



Radiochemistry for oncology and
cardiology (Arronax)
R&D on Liquid Xenon PET
autoradiography



X ray radiotherapy beam
profiler



Peroperatives probes
Preclinic imaging

